Positron emission tomography in urologic oncology

Cancer Control

Volumn 9, Issue 4, 2002, Pages 335-342

  Shvarts, Oleg ^a   Han, Ken Ryu ^a   Seltzer, Marc ^a   Pantuck, Allan J ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; AMMONIA N 13; DOPAMINE DERIVATIVE; FLOXURIDINE; FLOXURIDINE F 18; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; FLUOROTYROSINE F 18; GALLIUM EDETATE GA 68; NITROGEN 13; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; WATER O 15;

ADVANCED CANCER; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; KIDNEY CANCER; MEDICAL LITERATURE; NEPHRECTOMY; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROSTATE CANCER; REVIEW; TESTIS CANCER; UROGENITAL TRACT CANCER; UROLOGY;

EID: 0036639992     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900408     Document Type: Review

References (52)

1. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
2. Determination of malignancy of thyroid nodules with positron emission tomography
3. Differential diagnosis of lung tumor with positron emission tomography: A prospective study
4. Pre-operative staging of colorectal carcinoma using positron emission tomography
5. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer
6. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine-labeled deoxyglucose
7. Blood metabolism of [methyl-11C]choline: Implications for in vivo imaging with positron emission tomography
8. PET imaging of prostate cancer using carbon-11-choline
9. Comparison of [18F] fluorocholine and [18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer
10. Positron emission tomography in urologic oncology
11. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy
12. The increased accumulation of 18[F] fluorodeoxyglucose in untreated prostate cancer
13. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose
14. Experience with carbon-11 choline positron emission tomography in prostate carcinoma
15. Positron emission tomography with 18 fluorine-labeled deoxyglucose: Utility in localized and advanced prostate cancer
16. Comparison of helical computerized tomography, positron emission tomography, and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
17. Combined 18F-FDG and 11C-methionine PET Scans in patients with newly progressive metastatic prostate cancer
18. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET
19. Positron emission tomography in urological malignancy
20. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation
21. Reliability of CT in preoperative evaluation of bladder carcinoma
22. Diagnostic imaging of urothelial cancer
23. MR staging of bladder carcinoma: Correlation with pathologic findings
24. Bladder tumor staging: Comparison of contrast-enhanced CT, T1 and T2 weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadoliniumenhanced imaging
25. Preliminary assessment if fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer
26. Positron emission tomography in the diagnosis and staging of urinary bladder cancer
27. Positron emission tomography in diagnosis of renal cell carcinoma [German]
28. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma
29. Evaluation of renal cell carcinoma with whole body FDG PET
30. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer
31. Renal cell carcinoma: Clinical aspects, imaging diagnosis, and staging
32. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm
33. Intramedullary spinal cord metastasis from renal cell carcinoma: Detection by positron emission tomography
34. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan
35. Fluorodeoxyglucose PET in the initial staging of germ cell tumours
36. Surveillance following orchidectomy for stage I testicular seminoma
37. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumours
38. Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Intergroup Study
39. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors
40. Therapy control of metastatic testicular carcinoma with F18-DOG-PET
41. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients
42. FDG PET for detection and therapy control of metastatic germ cell tumour
43. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse
44. Imaging metastatic testicular germ cell tumours with 18 FDG positron emission tomography: Prospects for detection and management
45. Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan-Kettering Cancer Center
46. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience
47. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma
48. Predictive impact of 2-18-fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma
49. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET
50. Nuclear medicine in cancer diagnosis
51. Use of positron emission tomography in animal research
52. CL1-SR39: A non-invasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography